H. Lundbeck AS Class A HLUN A
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- DKK 32.50
- Day Range
- DKK 32.20–32.85
- 52-Week Range
- DKK 27.10–38.08
- Bid/Ask
- DKK 32.60 / DKK 32.70
- Market Cap
- DKK 32.44 Bil
- Volume/Avg
- 113,813 / 99,612
Key Statistics
- Price/Earnings (Normalized)
- 6.29
- Price/Sales
- 1.47
- Dividend Yield (Trailing)
- 2.31%
- Dividend Yield (Forward)
- 2.31%
- Total Yield
- 2.43%
Company Profile
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company’s portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson’s disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Mid Value
- Total Number of Employees
- 5,700
- Website
- https://www.lundbeck.com
Competitors
Valuation
|
Metric
|
HLUN A
|
ALNY
|
EXEL
|
|---|---|---|---|
Price/Earnings (Normalized) | 6.29 | — | 21.22 |
Price/Book Value | 1.33 | — | 2.93 |
Price/Sales | 1.47 | 9.26 | 3.62 |
Price/Cash Flow | 5.84 | 86.87 | 19.50 |
Price/Earnings
HLUN A
ALNY
EXEL
Financial Strength
|
Metric
|
HLUN A
|
ALNY
|
EXEL
|
|---|---|---|---|
Quick Ratio | 1.08 | 2.86 | 3.23 |
Current Ratio | 1.66 | 3.08 | 3.46 |
Interest Coverage | 54.83 | −3.36 | — |
Quick Ratio
HLUN A
ALNY
EXEL
Profitability
|
Metric
|
HLUN A
|
ALNY
|
EXEL
|
|---|---|---|---|
Return on Assets (Normalized) | 11.26% | −2.47% | 9.61% |
Return on Equity (Normalized) | 19.24% | — | 12.20% |
Return on Invested Capital (Normalized) | 15.53% | −7.00% | 8.59% |
Return on Assets
HLUN A
ALNY
EXEL
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Hjrcprsp | Tcdw | $79.1 Bil | |
MKKGY
| Merck KGaA ADR | Syqpknpxbp | Sqzkty | $74.3 Bil | |
HLN
| Haleon PLC ADR | Yfljxrdvl | Mrbn | $38.1 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Qgkphxxx | Tpds | $19.1 Bil | |
VTRS
| Viatris Inc | Vmhcvtdp | Rnlq | $13.2 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Tnxkjjv | Sptk | $11.7 Bil | |
CTLT
| Catalent Inc | Gxghvvffj | Fmsnkkg | $10.0 Bil | |
CURLF
| Curaleaf Holdings Inc | Jpldcsxh | Tgb | $4.2 Bil | |
PRGO
| Perrigo Co PLC | Nypfnhspt | Mpwg | $4.1 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Vxtxghzt | Wwtspy | $3.3 Bil |